A Phase I Study of MK-0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase I Study of MK-0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Dalotuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 13 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top